Drugs / AKB-4924
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02914262 | Aug → Nov 2016 | inflammatory bowel disease | Aerpio Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AKB-4924 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02914262 ↗ |
| Route | Oral | “Single oral doses of AKB-4924 will be investigated” NCT02914262 ↗ |